* Using Marengo's TriSTAR platform, Ipsen and Marengo teams expand their
ongoing oncology research to include up to two additional assets in new
early development collaboration
* Research will focus on using Marengo's TriSTAR platform to reinvigorate and
mobilize selective V? T cells to boost anti-tumor activity in patients with
traditionally difficult-to-treat 'cold' tumors
PARIS, FRANCE, and CAMBRIDGE, MA, U.S., 07 June 2024 - Ipsen (Euronext: IPN;
ADR: IPSEY) and Marengo Therapeutics Inc, a clinical-stage biotech company,
announced today the expansion of their ongoing oncology research partnership, to
include TriSTAR, Marengo's next-generation, precision T cell engager (TCE)
technology. Traditional TCEs targeting 'cold' tumors have limited efficacy due
to poor T cell quality and exhaustion. Marengo's proprietary first-in-class
TriSTAR TCEs have the potential to overcome these limitations, redirecting a new
and expanded pool of highly activated memory V? T cells to the tumor. The teams
will focus on exploring potential in 'cold' tumors which typically fail to
trigger a strong immune response when treated with TCEs.
"We take a science-first approach to expanding our pipeline and are delighted to
continue our strong work with the teams at Marengo, who share our passion and
drive to accelerate cancer innovations," said David Jenkins, SVP, Research and
External Innovation at Ipsen. "Through Marengo's next-generation TriSTAR
platform we have the potential to unlock the power of the immune system,
activating a wider pool of T cells to eradicate tumors that traditionally have a
weak response to T-cell immunotherapies."
"We are excited to build on our existing research collaboration with Ipsen,
which has already successfully delivered the first development candidate earlier
this year," said Zhen Su, CEO of Marengo Therapeutics. "This new collaboration
with Ipsen builds on our clinically validated TCR V? platform and our internal
work with new TriSTAR T cell engagers that suggest best-in-class potential and
the ultimate precision IO goal of delivering the right T cells to the right
tumor. The TriSTAR platform significantly expands our portfolio to target
difficult-to-treat 'cold' tumors, and we are thrilled to partner with the Ipsen
oncology team to realize this ambition together."
Under the terms of the agreement, Ipsen will assume responsibility for all
activities following development candidate nomination. Marengo will receive an
upfront payment and potential payments up to a total of $1.2 billion if all
milestones are met in addition to tiered sales royalty payments.
ENDS
About Ipsen
We are a global biopharmaceutical company with a focus on bringing
transformative medicines to patients in three therapeutic areas: Oncology, Rare
Disease and Neuroscience.
Our pipeline is fueled by external innovation and supported by nearly 100 years
of development experience and global hubs in the U.S., France and the U.K. Our
teams in more than 40 countries and our partnerships around the world enable us
to bring medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored
Level I American Depositary Receipt program (ADR: IPSEY). For more information,
visit ipsen.com.
About Marengo
Marengo Therapeutics, Inc, a clinical-stage biotech company, develops novel TCR-
targeting antibodies that selectively modulate common and disease-specific T
cell subsets of the germline TCR repertoire to provide lifelong protection
against cancer and other diseases. With a passionate team of dedicated
scientists experienced in immunology and oncology, Marengo's proprietary
Selective T Cell Activation Repertoire (STAR) platform leverages an extensive
biological understanding of T cell function and receptor signaling to create a
world in which everyone's immune system can defeat cancer. To learn more, visit
marengotx.com.
About TriSTAR Platform
Marengo's TriSTAR platform is a multi-specific antibody-fusion platform derived
from Marengo's proprietary library of antibodies targeting germline-encoded
variable V? regions of the TCR, fused to a T cell co-stimulatory moiety and a
tumor-associated antigen binder. By expanding and redirecting a new pool of
highly activated memory V? T cells, TriSTAR TCEs have the potential to overcome
the effects of poor T cell quality and T cell exhaustion that may limit the
activity of traditional TCEs.
Email: corporate.communications@ipsen.com
(mailto:corporate.communications@ipsen.com)
Ipsen contacts
Investors
Craig Marks | + 44 7584 349 193
Nicolas Bogler | +33 (0) 6 52 19 98 92
Media
Amy Wolf | +41 7 95 76 07 23
Jess Smith | + 44 7557 267 634
Marengo contacts
Investors
Svetlana Makhni | smakhni@marengotx.com
Media
Peg Rusconi | peg.rusconi@vergescientific.com
Disclaimers and/or Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are
based on Ipsen's management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect Ipsen's future ability
to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today. Use of the
words 'believes', 'anticipates' and 'expects' and similar expressions are
intended to identify forward-looking statements, including Ipsen's expectations
regarding future events, including regulatory filings and determinations.
Moreover, the targets described in this document were prepared without taking
into account external-growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend on conditions
or facts likely to happen in the future, and not exclusively on historical data.
Actual results may depart significantly from these targets given the occurrence
of certain risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being launched on
the market or reaching its commercial targets, notably for regulatory or
competition reasons. Ipsen must face or might face competition from generic
medicine that might translate into a loss of market share. Furthermore, the
research and development process involves several stages each of which involves
the substantial risk that Ipsen may fail to achieve its objectives and be forced
to abandon its efforts with regards to a medicine in which it has invested
significant sums. Therefore, Ipsen cannot be certain that favorable results
obtained during preclinical trials will be confirmed subsequently during
clinical trials, or that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the medicine concerned. There can
be no guarantees a medicine will receive the necessary regulatory approvals or
that the medicine will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking
statements. Other risks and uncertainties include but are not limited to,
general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and healthcare legislation; global trends
toward healthcare cost containment; technological advances, new medicine and
patents attained by competitors; challenges inherent in new-medicine
development, including obtaining regulatory approval; Ipsen's ability to
accurately predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of Ipsen's patents and other protections for
innovative medicines; and the exposure to litigation, including patent
litigation, and/or regulatory actions. Ipsen also depends on third parties to
develop and market some of its medicines which could potentially generate
substantial royalties; these partners could behave in such ways which could
cause damage to Ipsen's activities and financial results. Ipsen cannot be
certain that its partners will fulfil their obligations. It might be unable to
obtain any benefit from those agreements. A default by any of Ipsen's partners
could generate lower revenues than expected. Such situations could have a
negative impact on Ipsen's business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or revise any
forward-looking statements, targets or estimates contained in this press release
to reflect any change in events, conditions, assumptions or circumstances on
which any such statements are based, unless so required by applicable law.
Ipsen's business is subject to the risk factors outlined in its registration
documents filed with the French Autorité des Marchés Financiers. The risks and
uncertainties set out are not exhaustive and the reader is advised to refer to
Ipsen's latest Universal Registration Document, available on ipsen.com
(https://www.globenewswire.com/Tracker?data=cRbeTYiLm_i554EQ7ITgGkjFSkEO7CuADsdG
INJYRhuLZP1b2RRGQKaNMQhqDBefwdyOcUcRf2VYKHI9RWUEWA==).
Â